Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Shionogi secures $482m BARDA contract to tackle AMR crisis
  • M&A / Deals

Shionogi secures $482m BARDA contract to tackle AMR crisis

Pharmaceutical Technology

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

M&A / DealsInfectious DiseaseRead full story

pharminent April 9, 2026 (Last updated: April 9, 2026)

Pharmaceutical Technology

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

M&A / DealsInfectious DiseaseRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sidewinder secures $137M to advance ‘precision’ ADCs
Next: Syneron raises $150m for macrocyclics, and other financings

Related Stories

  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
  • M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.